Dostarlimab

Jemperli 500 MG Concentrado Para Solucion Para Perfusion

500 mg concentrado para solución para perfusiónSpainMarketedAuthorised 8 Aug 2025

In other countries

The same active substances on other registers, the same brand first.

JemperliBrazil · Glaxosmithkline Brasil LtdaSame brand
JemperliCanada · 50 MG / ML · Solution · Glaxosmithkline INCSame brand
JemperliEuropean Union · GlaxoSmithKline Trading Services LimitedSame brand
JemperliCroatiaSame brand
JemperliItaly · Soluzione per infusione · Glaxosmithkline Trading Services LimitedSame brand
Jemperli 500 mg oplossing voor infusieNetherlands · Oplossing voor infusie · GlaxoSmithKline Trading Services LimitedSame brand
Jemperli Concentrate for Solution for Infusion 500MG/10MLSingapore · 500mg/10mL · infusion, solution concentrate · Glaxosmithkline Pte LTDSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Dostarlimab

Jemperli 500 MG Concentrado Para Solucion Para Perfusion

500 mg concentrado para solución para perfusiónSpainMarketedAuthorised 8 Aug 2025

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

JemperliUnited States · 500MG/10ML · injectable · Glaxosmithkline

Packs

Pack	Code	Status
JEMPERLI 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSION, 1 vial de 10 ml	768285

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Dostarlimab
Strength: 500 mg
Dosage form: concentrado para solución para perfusión
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 8 Aug 2025
Registration: 1211538001IP
Marketing authorisation holder: Glaxosmithkline (Ireland) Limited
Procedure: EU centralised
Supply: Uso Hospitalario